Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis C

NCT01859962 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

38

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Hepatitis C

Interventions

DRUG: PPI-668
DRUG: BI 207127 Dose 1
DRUG: BI 207127 Dose 2
DRUG: Faldaprevir
DRUG: Ribavirin
DRUG: BI 207127 Placebo

Sponsor

Presidio Pharmaceuticals, Inc.

Collaborators

[object Object]